Edition:
United States

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

32.70USD
28 Apr 2017
Change (% chg)

$-0.04 (-0.13%)
Prev Close
$32.74
Open
$32.62
Day's High
$36.82
Day's Low
$32.54
Volume
390,065
Avg. Vol
1,225,416
52-wk High
$36.82
52-wk Low
$25.25

Latest Key Developments (Source: Significant Developments)

Roche's O'Day says has seen no more thromboembolic events with ACE910
Thursday, 27 Apr 2017 09:36am EDT 

April 27 (Reuters) - Roche :Drugs head Dan O'Day says access limitations for multiple sclerosis medicine Ocrevus in United States 'are really none'.Says he is hopeful ACE910 will be available to hemophilia patients by end of 2017, early 2018.O'Day says has seen no more significant thromboembolic events with ACE910 beyond those already reported.Says Lucentis sales seen rising in FY2017, though pace may slow from 9 percent in first quarter.  Full Article

BD licenses molecular indexing technology to Roche
Wednesday, 26 Apr 2017 06:59am EDT 

April 26 (Reuters) - Becton Dickinson And Co ::Becton Dickinson And Co - has non-exclusively licensed its patented stochastic labelling technology to Roche for multiple commercial applications.Becton Dickinson And Co - specific financial terms of agreement have not been disclosed.  Full Article

Roche Holding says strategic alliance with Sentara
Wednesday, 19 Apr 2017 07:00am EDT 

April 19 (Reuters) - Roche Holding Ag ::Establishment of a strategic alliance with Sentara Consolidated Laboratories of Norfolk, VA.  Full Article

FDA grants Genentech’s tecentriq accelerated approval
Monday, 17 Apr 2017 09:15pm EDT 

April 17 (Reuters) - Roche Holding Ag ::FDA grants Genentech’s tecentriq (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer.Genentech - "it is not known if tecentriq is safe and effective in children".  Full Article

Genentech says U.S. FDA approves Lucentis (ranibizumab injection) for diabetic retinopathy
Monday, 17 Apr 2017 01:13pm EDT 

April 17 (Reuters) - Genentech::FDA approves Genentech’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States.FDA approved Lucentis 0.3 mg for monthly treatment of all forms of diabetic retinopathy.In analysis that supported approval, patients with/without DME in Lucentis group experienced improvements in severity of their retinopathy.  Full Article

Bristol-Myers Squibb enters into separate agreements with Biogen and Roche
Thursday, 13 Apr 2017 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to license anti-etau and anti-myostatin compounds, respectively . Bristol-Myers Squibb Co - to receive a combined $470m upfront, along with potential milestone payments and tiered double-digit royalties from each company . Bristol-Myers Squibb Co - under agreement to license BMS-986168, Biogen will pay to Bristol-Myers Squibb an upfront payment of $300 million . Bristol-Myers Squibb Co - Roche will pay to Bristol-Myers Squibb an upfront payment of $170 million with potential milestone payments of up to $205 million . Bristol-Myers Squibb says Roche will pay to Bristol-Myers Squibb an upfront payment of $170 million with potential milestone payments of up to $205 million .Bristol-Myers Squibb - Biogen also will assume all remaining obligations to former stockholders of ipierian inc related to co's acquisition of co in 2014.  Full Article

Roche launches anti-p504s (SP116) Rabbit Monoclonal Primary Antibody(2) for prostate cancer diagnosis
Wednesday, 12 Apr 2017 10:00am EDT 

Roche Holding AG : Roche launches antibody test to aid in diagnosis of challenging prostate cancer cases .Announced global launch of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody(2) for prostate cancer diagnosis.  Full Article

Roche's CINtec histology test receives FDA clearance
Wednesday, 5 Apr 2017 01:00am EDT 

Roche Holding Ag says : CINtec histology test receives FDA clearance . Roche's CINtec Histology test is the only clinically validated p16 immunohistochemistry test available globally . test helps pathologists determine which women should receive treatment for cervical pre-cancer Further company coverage: [ROG.S] (Reporting By Zurich newsroom) ((zurich.newsroom@thomsonreuters.com; +41 58 306 7336;)).  Full Article

Roche says study supports Alecensa for people with certain lung cancer
Monday, 3 Apr 2017 01:06am EDT 

Roche Holding Ag :Says phase iii alur study supports the use of alecensa for people with advanced alk-positive lung cancer.  Full Article

Genentech says FDA advisory committee unanimously recommends approval of co’s subcutaneous rituximab for certain blood cancers
Wednesday, 29 Mar 2017 12:09pm EDT 

Genentech: FDA advisory committee unanimously recommends approval of Genentech's subcutaneous rituximab for certain blood cancers .FDA is expected to make a decision on approval for rituximab by June 26, 2017.  Full Article

More From Around the Web

Photo

Swiss drugmaker Roche confident sales growth will overcome generic threat

ZURICH Swiss drugmaker Roche, encouraged by better than expected first-quarter sales, said it was confident new drugs will help to deliver revenue and profit growth even as its older medicines take a hit from cheaper copies.